世基生醫 (7595.TW) 2025Q2 financial report shows net profit of -41.33M TWD, with a YoY growth rate of 15.11%, clearly higher than last year, showing strong profit momentum and good management efficiency. It is recommended to monitor revenue, cash flow, and industry trends, and use Growin AI Value Analysis to seize growth opportunities. Overall, the company has shown a solid growth curve and future performance is worth watching.